Laurus Labs has announced its financial results for the fiscal year ending March 31, 2026, reporting a revenue of ₹6,813 crore, marking a 23% increase over the previous year. The company achieved an EBITDA of ₹1,826 crore, reflecting a 64% growth, with EBITDA margins improving to 26.8% from 20.1% in FY25.
The Hyderabad-based pharmaceutical and biotech company attributed its robust performance to strong growth in its Contract Development and Manufacturing Organisation (CDMO) division and sustained demand across its complex chemistry platforms. The Affordable Medicines division also contributed significantly, with revenues reaching ₹4,733 crore, an 18% increase from the previous year.
In the fourth quarter of FY26, Laurus Labs reported revenues of ₹1,812 crore, a 5% year-on-year growth, and an EBITDA of ₹523 crore, up by 10% compared to Q4 FY25. The company’s gross margins for the quarter stood at 61.4%, an improvement from the previous year’s 54.5%.
Dr. Satyanarayana Chava, Founder and CEO of Laurus Labs, highlighted the company’s strategic investments in novel technologies and its resilient business model amidst macro-economic volatility. He noted the company’s continued progress in EHS/ESG initiatives and its focus on laying a foundation for future growth.
The CDMO division, particularly in small molecules, reported a 38% increase in revenues to ₹1,896 crore for FY26, driven by late-stage pipeline developments and commercial NCE API supplies. The Bio division also showed healthy growth, with revenues increasing by 15% to ₹184 crore.
Laurus Labs declared a second interim dividend of ₹1.2 per share during Q4 FY26. The company plans to increase its capital expenditure intensity over FY27-28 to support growth projects across various sectors, including small molecule, fermentation, peptides, and gene therapy/ADC.
The company completed 132 quality audits in FY26 without critical findings and was listed in the S&P Global Sustainability Yearbook for 2024 and 2025. Laurus Labs remains committed to the United Nations Global Compact’s sustainability principles.
An earnings conference call is scheduled for April 30, 2026, at 5:00 p.m. IST to discuss the results in detail.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).